OncoCyte Corp reports results for the quarter ended in June - Earnings Summary

Insight Molecular Diagnostics

10/08/2023 15:10

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of
$1.07​​ per share for the quarter ended in June. The mean
expectation of five analysts for the quarter was for a loss
of 87 cents per share.
    * Revenue fell 77.6% to $463.00 thousand from a year ago;
analysts
expected $362.50 thousand. 
    * OncoCyte Corp's reported EPS for the quarter was a loss of
$1.07​.
    * The mean earnings estimate of analysts had risen by
about 13.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * OncoCyte Corp shares had fallen by 23.7% this quarter and
lost 45.3% so far this year.
    * The company reported a quarterly loss of $8.33 million.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$7.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 02:10 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.87          -1.07          Missed
 Mar. 31 2023      -1.70          0.40           Beat
 Dec. 31 2022      -1.88          -8.00          Missed
 Sep. 30 2022      -2.26          -1.60          Beat